+

WO2003014745A3 - Procede d'identification de substances ayant une influence positive sur les affections inflammatoires - Google Patents

Procede d'identification de substances ayant une influence positive sur les affections inflammatoires Download PDF

Info

Publication number
WO2003014745A3
WO2003014745A3 PCT/EP2002/007937 EP0207937W WO03014745A3 WO 2003014745 A3 WO2003014745 A3 WO 2003014745A3 EP 0207937 W EP0207937 W EP 0207937W WO 03014745 A3 WO03014745 A3 WO 03014745A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory drugs
identifying anti
nhr
identifying
inflammatory
Prior art date
Application number
PCT/EP2002/007937
Other languages
English (en)
Other versions
WO2003014745A2 (fr
Inventor
Birgit Jung
Norbert Kraut
Stefan Mueller
Original Assignee
Boehringer Ingelheim Pharma
Birgit Jung
Norbert Kraut
Stefan Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Birgit Jung, Norbert Kraut, Stefan Mueller filed Critical Boehringer Ingelheim Pharma
Priority to EP02754896A priority Critical patent/EP1425587A2/fr
Priority to JP2003519426A priority patent/JP2005503787A/ja
Priority to MXPA04001128A priority patent/MXPA04001128A/es
Priority to CA002453913A priority patent/CA2453913A1/fr
Priority to AU2002321229A priority patent/AU2002321229A1/en
Publication of WO2003014745A2 publication Critical patent/WO2003014745A2/fr
Publication of WO2003014745A3 publication Critical patent/WO2003014745A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des protéines NHR impliquées dans des processus inflammatoires. L'invention concerne également la modulation de la fonction desdites protéines NHR, cette modulation permettant d'exercer une influence positive sur les maladies inflammatoires.
PCT/EP2002/007937 2001-08-06 2002-07-17 Procede d'identification de substances ayant une influence positive sur les affections inflammatoires WO2003014745A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02754896A EP1425587A2 (fr) 2001-08-06 2002-07-17 Procede d'identification de substances anti-inflammatoirs
JP2003519426A JP2005503787A (ja) 2001-08-06 2002-07-17 炎症症状にポジティブに影響を与える物質の特定方法
MXPA04001128A MXPA04001128A (es) 2001-08-06 2002-07-17 Metodo para identificar sustancias que afectan realmente condiciones inflamatorias.
CA002453913A CA2453913A1 (fr) 2001-08-06 2002-07-17 Procede d'identification de substances ayant une influence positive sur les affections inflammatoires
AU2002321229A AU2002321229A1 (en) 2001-08-06 2002-07-17 Method for identifying anti-inflammatory drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01119003.0 2001-08-06
EP01119003 2001-08-06

Publications (2)

Publication Number Publication Date
WO2003014745A2 WO2003014745A2 (fr) 2003-02-20
WO2003014745A3 true WO2003014745A3 (fr) 2004-03-25

Family

ID=8178260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007937 WO2003014745A2 (fr) 2001-08-06 2002-07-17 Procede d'identification de substances ayant une influence positive sur les affections inflammatoires

Country Status (6)

Country Link
EP (1) EP1425587A2 (fr)
JP (1) JP2005503787A (fr)
AU (1) AU2002321229A1 (fr)
CA (1) CA2453913A1 (fr)
MX (1) MXPA04001128A (fr)
WO (1) WO2003014745A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074969A2 (fr) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024471A1 (fr) * 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Recepteur d'opiaces, de cannabinoides et d'oestrogenes
WO2000053563A1 (fr) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Nouveaux ligands de recepteurs nucleaires ppar
WO2001022988A1 (fr) * 1999-09-30 2001-04-05 Aubin Jane E Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse
WO2002052270A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode permettant d'identifier des substances qui influencent positivement des affections inflammatoires de maladies chroniques inflammatoires des voies respiratoires
WO2002052036A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede d'identification de substances ayant une influence positive sur les conditions inflammatoires des maladies inflammatoires chroniques des voies aeriennes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024471A1 (fr) * 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Recepteur d'opiaces, de cannabinoides et d'oestrogenes
WO2000053563A1 (fr) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Nouveaux ligands de recepteurs nucleaires ppar
WO2001022988A1 (fr) * 1999-09-30 2001-04-05 Aubin Jane E Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse
WO2002052270A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode permettant d'identifier des substances qui influencent positivement des affections inflammatoires de maladies chroniques inflammatoires des voies respiratoires
WO2002052036A2 (fr) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede d'identification de substances ayant une influence positive sur les conditions inflammatoires des maladies inflammatoires chroniques des voies aeriennes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUCLEAR RECEPTORS NOMENCLATURE COMMITTEE, 1999: "A unified nomenclature system for the nuclear receptor superfamily.", CELL, vol. 97, 16 April 1999 (1999-04-16), pages 161 - 163, XP002267664 *

Also Published As

Publication number Publication date
JP2005503787A (ja) 2005-02-10
CA2453913A1 (fr) 2003-02-20
MXPA04001128A (es) 2004-05-20
AU2002321229A1 (en) 2003-02-24
WO2003014745A2 (fr) 2003-02-20
EP1425587A2 (fr) 2004-06-09

Similar Documents

Publication Publication Date Title
AU2002305793A1 (en) Database access bridge system and process
AU2002251612A1 (en) Stent and method for the production thereof (variants)
AU2002358270A1 (en) Zero-order sustained released dosage forms and method of making the same
AU2002364528A1 (en) Bio-implant and method of making the same
WO2002097130A3 (fr) Microstructures et leur utilisation pour l'evolution orientee de biomolecules
AU4279000A (en) Bolted metal joist and method of manufacturing the same
AU2002250858A1 (en) Capsule-in-capsule system and method for the production thereof
AU2002363345A1 (en) Method for the production of fuel from acid fats and system for carrying out said method
WO2003102012A3 (fr) Nouveaux esters d'etonogestrel
EP1326306A3 (fr) Contact pour un câble plat et méthode de branchement du contact au câble plat
AU2002245472A1 (en) An automated bidding process and system
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
AU2002253691A1 (en) Lamp and method of manufacturing the same
AU2002364914A1 (en) Computer-implemented system and method for productivity enhancement
AU2002301109A1 (en) Method for the prediction of preeclampsia and other diseases
WO2003014745A3 (fr) Procede d'identification de substances ayant une influence positive sur les affections inflammatoires
WO2004016640A3 (fr) Intermediaires de 5 androstene-3?-ol steroides et leurs procedes de preparation
AU2002250831A1 (en) Method for the production of sputtering targets
WO2002052270A3 (fr) Methode permettant d'identifier des substances qui influencent positivement des affections inflammatoires de maladies chroniques inflammatoires des voies respiratoires
AU2002308805A1 (en) Magnesium-based alloy and method for the production thereof
AU2002308806A1 (en) Magnesium-based alloy and method for the production thereof
WO2003031584A3 (fr) Reparation d'axone
AU2001276049A1 (en) Method of enabling the spacing of metal units
WO2002052269A3 (fr) Procede d'identification de substances qui influencent de maniere positive des troubles inflammatoires de maladies inflammatoires chroniques des voies respiratoires
AU2002250813A1 (en) Pesticide and method for the production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2453913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002754896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001128

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003519426

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002754896

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002754896

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载